Citigroup
CRBP icon

Citigroup’s Corbus Pharmaceuticals CRBP Stock Holding History

Citigroup’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-117
Closed -$19K – 7622
2019
Q4 		$19K Sell
117
-846
-88% -$125K ﹤0.01% 6947
2019
Q3 		$141K Sell
963
-1,090
-53% -$190K ﹤0.01% 5428
2019
Q2 		$427K Buy
2,053
+1,460
+246% +$313K ﹤0.01% 4573
2019
Q1 		$124K Sell
593
-480
-45% -$106K ﹤0.01% 5545
2018
Q4 		$188K Sell
1,073
-597
-36% -$119K ﹤0.01% 5076
2018
Q3 		$378K Buy
1,670
+1,490
+828% +$241K ﹤0.01% 4606
2018
Q2 		$27K Sell
180
-180
-50% -$32.7K ﹤0.01% 6765
2018
Q1 		$66K Buy
360
+120
+50% +$26.9K ﹤0.01% 5962
2017
Q4 		$51K Buy
240
+90
+60% +$19.3K ﹤0.01% 6167
2017
Q3 		$32K Sell
150
-483
-76% -$94.5K ﹤0.01% 6216
2017
Q2 		$120K Buy
633
+103
+19% +$20.2K ﹤0.01% 5204
2017
Q1 		$131K Buy
+530
New +$130K ﹤0.01% 4995

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup's CRBP Position: Q1 2026 in Review

Citigroup increased its Corbus Pharmaceuticals (CRBP) stake by 218% in Q1 2026, buying an estimated $96.4K and bringing the position to 16,708 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #4094.

Citigroup first reported a position in CRBP in Q1 2017 and has held it in 28 quarters since. The position peaked at $685K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Citigroup held 16,708 shares of Corbus Pharmaceuticals worth $157K as of Q1 2026.
  • Citigroup bought 11,454 Corbus Pharmaceuticals shares in Q1 2026, an estimated $96.4K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4094 holding.
  • Citigroup first reported a position in Corbus Pharmaceuticals in Q1 2017 and has held it in 28 quarters since.
  • Citigroup's Corbus Pharmaceuticals position peaked at $685K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.